Some Jolly Rancher sweets unsafe to eat, FSA says
A number of products from a brand of US sweets are "unsafe to eat" and contain ingredients which could damage DNA and increase the risk of cancer, the Food Standards Agency (FSA) has warned.
UK businesses and consumers are being urged to stop buying and selling the Jolly Ranchers products, owned by US company Hershey.
The FSA says they contain chemical compounds - mineral oil aromatic hydrocarbons (MOAH) and mineral oil saturated hydrocarbons (MOSH) - which are "not compliant with UK laws".
The products pose a safety risk if consumed regularly over time but there is "no immediate cause for concern, as [the] food safety risk is low", the agency adds.
In a food alert published on Wednesday evening, the FSA said: "MOAH can cause damage to DNA and has the potential to increase the risk of cancer, particularly if consumed in high quantities over a prolonged period of time.
"MOAH is a genotoxic carcinogen, therefore no exposure is without risk to human health."
MOAH and MOSH are used in confectionary to prevent stickiness and create a glossy appearance.
According to the agency, The Hershey Company has been working with the UK government body to remove the affected Jolly Rancher products from the UK market since 2024, but some businesses in Britain have continued to import the products.
The affected products are: Jolly Rancher Hard Candy, Jolly Rancher 'Misfits' Gummies, Jolly Rancher Hard Candy Fruity 2 in 1, and Jolly Ranchers Berry Gummies.
The food agency is advising people who have any of the listed products to not eat them and dispose of them at home. If consumers have any concerns, they are being asked to notify the Trading Standards department or environmental health department in the local authority they made the purchase from.
The agency said it was asking enforcement authorities to make "immediate contact" with businesses which had been supplied with or received any of the products, and take action to ensure they were withdrawn from the market.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Vasodilators Show Severity-Dependent Effects in SSc-ILD
Vasoactive vasodilating drugs (VVDs) have differential effects on the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD), according to a post hoc analysis of prospectively collected data. Prostanoids were associated with protective benefits in patients with mild vasculopathy, while endothelin-receptor antagonists (ERAs) were linked to a lower risk of worsening symptoms in patients with more severe disease. METHODOLOGY: Researchers conducted a post-hoc analysis of prospectively collected data from the European Scleroderma Trials and Research group (EUSTAR) database. The analysis included 2156 patients with SSc-ILD, confirmed by high-resolution CT, with 5996 yearly visits. VVD treatment included ERAs, phosphodiesterase-5 inhibitors, and prostanoids that had been administered for at least 3 months during the study period. Progression outcomes were assessed within intervals of 9-15 months using three definitions: progression A (forced vital capacity [FVC] decline ≥ 10% or FVC decline of 5%-9% with a ≥ 15% decrease in diffusing capacity of the lungs for carbon monoxide [DLCO]), progression B (FVC decline ≥ 5% or DLCO decline ≥ 10%), and progression C (New York Heart Association functional class worsening). TAKEAWAY: A total of 80% of the patients were women, with 51% having diffuse skin involvement and 56.5% being Scl-70 positive. Prostanoids showed a protective association in patients without digital ulcers against progression A (odds ratio [OR], 0.61; 95% CI, 0.46-0.83) and progression B (OR, 0.76; 95% CI, 0.60-0.94) ERAs were linked to a protective effect against New York Heart Association class worsening (OR, 0.42; 95% CI, 0.21-0.86), regardless of digital ulcer presence. Over the median 5.6-year follow-up, VVD exposure had no effect on mortality. IN PRACTICE: "The beneficial effects of VVDs appear to depend on the severity of the vasculopathy, but further studies are needed to confirm the long-term benefits of VVDs in SSc-ILD,' said study author Adela-Cristina Sarbu, MD, of University Hospital Zurich and Bern University Hospital in Switzerland. SOURCE: Sarbu presented abstract OP0003 at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. LIMITATIONS: This is an observational study with long follow-up periods during which there were changes in clinical practice and treatment guidelines. There was high heterogeneity in the study population and missing data, including insufficient data to access radiological progression by high-resolution CT. DISCLOSURES: Sarbu had no financial disclosures or conflicts of interest to report. Some other study authors had financial relationships with many pharmaceutical companies, some of which market VVDs.
Yahoo
5 hours ago
- Yahoo
'Prostate cancer diagnosis felt like a black hole'
A man diagnosed with incurable prostate cancer said the news felt like falling into a "black hole", as he urged others to check for signs of the disease. Danny Burkey, from Ossett, was diagnosed in 2021, and was told his condition was incurable after a bone scan. The 59-year-old spoke as Prostate Cancer UK launched a campaign urging men to visit their GP with prostate concerns, in the hope of an early diagnosis. Mr Burkey told BBC Radio Leeds: "You think it is always going to happen to somebody else; you just cannot believe it is you." Mr Burkey sought a diagnosis after experiencing symptoms related to prostate cancer. According to the NHS, symptoms can include: Having a sudden urge to urinate Getting up often in the night to urinate Blood in your urine Erectile dysfunction. "I had a blood test, an MRI and a biopsy," Mr Burkey said. Recalling being told his illness was incurable, he said: "You are almost standing next to yourself thinking, I do not know what to do with this. "You just cannot process it." According to Prostate Cancer UK, one in eight men will get prostate cancer. It is now England's most common cancer. Despite the prevalence, the charity's research suggests six in 10 men are concerned about having a Digital Rectal Exam (DRE). Of those, over a third would not speak to a GP about prostate worries because they feared the DRE exam. Mr Burkey urged men to seek a diagnosis despite barriers, saying: "You do not need to have a DRE now. "You can ask your GP for a simple blood test and that gets the ball rolling, it is as simple as that." Earlier this week, the British Association of Urological Surgeons urged GPs to stop using the "outdated" and "inaccurate" DRE as a standard test. They labelled it a "poor test" that deterred men from coming forward. Men are encouraged to use Prostate Cancer UK's 30-second online risk checker and to talk to their GP about the prostate-specific antigen (PSA) blood test. A high level of PSA in the blood can indicate prostate cancer. Research led by Prostate Cancer UK shows that the way prostate cancer is diagnosed - with a PSA blood test followed by an MRI scan - reduces potential harms to men by 79%. Among those to catch the disease early was actor Colin McFarlane. McFarlane, who has appeared in The Dark Knight and Doctor Who, announced he had prostate cancer on the BBC Breakfast sofa in June 2023. He said: "I'm really lucky I caught it early, so I thought if I'm lucky and I know so much about this, I need to try and share this knowledge." McFarlane's friend, theatre director Femi Elufowoju Jr said hearing his story encouraged him to get checked, which led him to also being diagnosed. He thanked McFarlane for saving his life. Despite treatment, including chemotherapy and radiotherapy, Mr Burkey's body has stopped responding to advanced hormone therapy. He said: "Inevitably your body becomes resistant, the cancer becomes resistant to them. "You are constantly having your PSA levels monitored to see how treatments are working. "You are constantly sort of on your toes thinking where am I up to now? "What have I still got left that can be used? "It is a very anxious time. "I do not want another man to be in the position I am in." Listen to highlights from West Yorkshire on BBC Sounds, catch up with the latest episode of Look North. 'Colin McFarlane saved my life', says director 'Going from cancer doctor to patient was bizarrely reassuring' NHS Prostate Cancer UK
Yahoo
5 hours ago
- Yahoo
Woman with dementia recognised in King's Birthday Honours for her advocacy work
A woman with dementia who is trying to help others with the syndrome has been recognised for her work in the King's Birthday Honours. Christine Maddocks, from Eastbourne, was just 60 when she was diagnosed with vascular dementia, and since then she has also been diagnosed with Parkinson's disease and dementia with Lewy bodies, meaning an abnormal buildup of proteins. Following her diagnosis, Ms Maddocks has used her own experiences to help others understand more about dementia. She has now been awarded a British Empire Medal (BEM) in recognition of her outstanding advocacy for people living with dementia. You can see the full list of those honoured from Sussex here The retired police officer describes herself as a dementia activist, giving talks and lectures to a variety of audiences to educate others about the realities of living with the condition. Becoming actively involved with the dementia movement has given Ms Maddocks a renewed sense of purpose. In October 2022, Ms Maddocks was appointed as a trustee for Alzheimer's Society, the UK's leading dementia charity. Alzheimer's Society provides dementia support, funds groundbreaking research and campaigns to make dementia a priority. Corinne Mills, Interim CEO, for Alzheimer's Society said: 'Chris Maddocks has been recognised with a BEM for her significant advocacy and awareness for Lewy body dementia and LGBTQ+ dementia communities. Her insight, courage, and commitment to a "high challenge, high support" approach on the board at Alzheimer's Society has influenced our work in meaningful ways. "Chris's impact reaches beyond our organisation. Her leadership, shaped by lived experience, continues to challenge stigma and promote understanding.' The investiture ceremony will take place later this year at a royal venue where Ms Maddocks will receive the honours from a member of the Royal Family. If you are worried about dementia, Alzheimer's Society can help. Call its Dementia Support Line on 0333 150 3456 or visit
